{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:14:51Z","timestamp":1777958091934,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rosacea is a chronic inflammatory dermatosis. While standard therapies exist, managing refractory subtypes remains a therapeutic challenge. Oral Janus kinase (JAK) inhibitors have emerged as potential alternatives, but systematic evidence is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of oral JAK inhibitors for rosacea through a systematic review and meta\u2010analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search was conducted in five databases from inception to December 1, 2025. The primary outcome was the pooled clinical response rate. Secondary outcomes included the Investigator's Global Assessment (IGA), Clinician's Erythema Assessment (CEA), and Dermatology Life Quality Index (DLQI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven studies involving 57 patients were included. The overall pooled response rate was 89.9% (95% CI: 74.4%\u201399.4%), with low heterogeneity (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200916.3%). Regarding secondary outcomes, 67.8% of patients achieved an IGA score of \u2264\u20091, and 74.6% achieved a CEA reduction of \u2265\u20092 points. DLQI score also decreased from 17.30\u2009\u00b1\u20093.80 to 10.00\u2009\u00b1\u20093.43. Adverse events were reported in 10.5% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oral JAK inhibitors show promising potential as a therapeutic option for refractory rosacea. However, given the small sample size and single\u2010arm design, these findings are exploratory. Large\u2010scale randomized controlled trials are urgently needed to validate these findings and guide stratified treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jocd.70791","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:58:04Z","timestamp":1773032284000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral\n                    <scp>JAK<\/scp>\n                    Inhibitors as a Promising Therapeutic Strategy for Refractory Rosacea: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9592-1672","authenticated-orcid":false,"given":"Yu","family":"Peng","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College Beijing University of Chinese Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzi","family":"Sun","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College Beijing University of Chinese Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College Beijing University of Chinese Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xubo","family":"Huang","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College Beijing University of Chinese Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengchuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dongfang Hospital Beijing University of Chinese Medicine  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15122"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16481"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18420"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.659171"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12903"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1546043"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.141"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082153"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403\u2010024\u201003314\u20104"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S522317"},{"key":"e_1_2_13_13_1","first-page":"660","article-title":"Observation on Efficacy of Abrocitinib for 6 Cases of Steroid\u2010Induced Rosacea\u2010Like Dermatitis [Chinese]","volume":"41","author":"Meng X.","year":"2024","journal-title":"Dermatology Bulletin"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1721727X241258794"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1416004"},{"key":"e_1_2_13_16_1","first-page":"66","article-title":"Therapeutic Evaluation of Tofacitinib in Three Cases of Refractory Rosacea [Chinese]","volume":"45","author":"Cao Y.","year":"2023","journal-title":"Journal Dermatol Venereol"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S440138"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1239869"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S392280"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15848"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.04.020"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.351"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367994"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403798"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013560"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754251325482"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.237"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241229365"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.028"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.12.960"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12307"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17817"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.06.028"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2397477"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011\u2010023\u201001789\u2010x"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70791","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.70791","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:52:55Z","timestamp":1777956775000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.70791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/jocd.70791"],"URL":"https:\/\/doi.org\/10.1111\/jocd.70791","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2026-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70791"}}